Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of JS005 in adults with active ankylosing spondylitis
CTR20240026Phase 2Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of roconkibart in ankylosing spondylitis (AS), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jan 2024; status: active.
02
Drugs
roconkibart
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20240026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240026.